2. Disease Areas
  3. Digestive system Disease

Digestive system Disease

Gastrointestinal System Disease encompasses disorders of the stomach and intestines, characterized by symptoms such as peeling tongue, catarrh, and blood in stool. Key genetic involvement includes the MIR199A1 gene, which plays a role in miRNAs associated with DNA damage response and cell differentiation pathways. Therapeutic agents like Rebamipide and Indomethacin are linked to this condition, with affected tissues primarily including the small intestine and liver.

 

Digestive system Disease (2):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N0385
    Gomisin J 66280-25-9 99.97%
    Gomisin J is a Schisandra chinensis-derived lignan that can inhibit multiple targets such as eNOS, AMPK (LKB1, CaMKIIβ), fetuin-A, NF-κB, Nrf2/HO-1, and can pass through the blood-brain barrier. Gomisin J increases NO bioavailability by activating eNOS, regulates lipid metabolism by activating the AMPK pathway, inhibits fetuin-A and NF-κB to exert anti-inflammatory effects, and activates Nrf2/HO-1 to enhance antioxidant capacity. Gomisin J has the activities of anti-hypertension, regulating liver lipid metabolism, and reducing cerebral ischemia-reperfusion injury, and can be used for research on hypertension, non-alcoholic fatty liver disease, cerebral ischemia-reperfusion injury, etc.
    Gomisin J
  • HY-E70064A
    Helicobacter pylori alpha-1,3-fucosyltransferase
    Helicobacter pylori alpha-1,3-fucosyltransferase (Hp3FT) catalyzes the glycosyl addition of fucose from the donor GDP-fucose to the acceptor N-acetyllactosamine.
    Helicobacter pylori alpha-1,3-fucosyltransferase